Latest & greatest articles for colorectal cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for colorectal cancer

1. Self-expandable metal stents for obstructing colonic and extracolonic cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline – Update 2020

389Introduction Colorectal cancer is one of the most common cancers world- wide, particularly in the economically developed world [1]. Large-bowel obstruction caused by advanced colonic cancer occurs in 8%–13% of colonic cancer patients [2–4]. The man- agementof thissevereclinicalconditionhasbeencontroversial [5].Over thelastdecade,manyarticleshavebeenpublishedon the subject of colonic stenting for malignant colonic obstruc- tion, including randomized controlled trials (RCTs) and sys- tematic reviews. Thereby (...) ThisGuidelineisanofficialstatementoftheEuropeanSo- cietyof Gastrointestinal Endoscopy(ESGE). Itis a revision of the previously published 2014 Guideline addressing the role of self-expandable metal stents for obstructing colonic and extracolonic cancer. ABBREVIATIONS ASA American Society for Anesthesiologists CI confidence interval CT computed tomography CTC computed tomography colonoscopy ECM extracolonic malignancy ESGE European Societyof Gastrointestinal Endoscopy GRADE Grading of Recommendations Assessment, De- velopment and Evaluation HR

2020 European Society of Gastrointestinal Endoscopy

2. Localised Colon Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

or tests using other markers (e.g. M2-PK) lack formal comparisons of their performance, and integration with other assays needs to be monitored. Screening for high-risk populations is covered in the ESMO guidelines for hereditary gastrointestinal cancer [11]. DIAGNOSIS Symptoms and signs Colon cancer arises from the mucosa of the bowel, growing both into the lumen and the bowel wall, and/or spreading to adjacent organs. Symptoms are associated with relatively large tumours and/or advanced disease (...) and Colon Cancer Outcome. JAMA Oncol. 2018; 4(3):309-315. 22. Duffy MJ, van Dalen A, Haglund C et al. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer. 2003; 39: 718–727. 23. Locker GY, Hamilton S, Harris J et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006; 24: 5313–5327. 24. van der Geest LG, Lam-Boer J, Koopman M et al. Nationwide trends in incidence

2020 European Society for Medical Oncology

3. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial

Actions Aged, 80 and over Actions Double-Blind Method Actions Female Actions Follow-Up Studies Actions Gastrointestinal Neoplasms / drug therapy* Actions Gastrointestinal Neoplasms / pathology Actions Gastrointestinal Stromal Tumors / drug therapy* Actions Gastrointestinal Stromal Tumors / pathology Actions Humans Actions Male Actions Middle Aged Actions Phenylurea Compounds / therapeutic use* Actions Prognosis Actions Pyridines / therapeutic use* Actions Survival Rate Actions Young Adult Actions (...) Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily

2020 EvidenceUpdates

4. An RCT of Fecal Immunochemical Test Colorectal Cancer Screening in Veterans Without Recent Primary Care

An RCT of Fecal Immunochemical Test Colorectal Cancer Screening in Veterans Without Recent Primary Care An RCT of Fecal Immunochemical Test Colorectal Cancer Screening in Veterans Without Recent Primary Care - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest public (...) new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Am J Prev Med Actions . 2020 Jul;59(1):41-48. doi: 10.1016/j.amepre.2020.02.014. An RCT of Fecal Immunochemical Test Colorectal Cancer Screening in Veterans Without Recent Primary Care , , , , , Affiliations Expand Affiliations 1 Corporal

2020 EvidenceUpdates

5. Comparative Evaluation of Participation and Diagnostic Yield of Colonoscopy vs Fecal Immunochemical Test vs Risk-Adapted Screening in Colorectal Cancer Screening: Interim Analysis of a Multicenter Randomized Controlled Trial (TARGET-C)

of Sciences/Zhejiang Cancer Hospital. 4 Department of Cancer Prevention, Hunan Cancer Hospital, Changsha, China. 5 Office of Cancer Prevention and Treatment, Xuzhou Cancer Hospital, Xuzhou, China. 6 Department of Cancer Prevention, Anhui Provincial Cancer Hospital, Hefei, China. 7 Department of Colorectal Surgery, Tumor Hospital of Yunnan Province/Third Affiliated Hospital of Kunming Medical University, Kunming, China. 8 Department of Medical Oncology, Institute of Cancer and Basic Medicine (ICBM (...) , China. 13 Department of NCD Prevention and Heath Education, Hefei Center for Disease Control and Prevention, Hefei, China. 14 Department of Cancer Prevention, Tumor Hospital of Yunnan Province/Third Affiliated Hospital of Kunming Medical University, Kunming, China. 15 Henan Office for Cancer Control and Research, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China. 16 Department of Epidemiology and Biostatistics, and the Ministry of Education Key Lab

2020 EvidenceUpdates

6. Is 45 really the new 50 in colorectal cancer screening?

Is 45 really the new 50 in colorectal cancer screening? Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,800 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care research. www.acfp.ca June 29, 2020 (...) Is 45 really the new 50 in colorectal cancer screening? Clinical Question: Should we lower the age that average risk patients commence colorectal cancer screening from 50 to 45? Bottom Line: In developed countries, the incidence of colorectal cancer in persons under 50 years old has increased by 20-30% in the last 20 years. However, the absolute risk increase is only 1-4 per 100,000 persons. Screening average risk patients under age 50 should not be encouraged at this time. Evidence: • Population

2020 Tools for Practice

7. Short-term Outcomes of Single-port Versus Multiport Laparoscopic Surgery for Colon Cancer: The SIMPLE Multicenter Randomized Clinical Trial

2017 at 7 sites in Korea. A total of 388 adults (aged 19-85 yrs) with clinical stage I, II, or III adenocarcinoma of the ascending or sigmoid colon were enrolled and randomized. The primary endpoint was 30-day postoperative complication rates. Secondary endpoints were the number of harvested lymph nodes, length of the resection margin, postoperative pain, and time to functional recovery (bowel movement and diet). Patients were followed for 30 days after surgery. Results: Among 388 patients, 359 (...) Short-term Outcomes of Single-port Versus Multiport Laparoscopic Surgery for Colon Cancer: The SIMPLE Multicenter Randomized Clinical Trial Short-term Outcomes of Single-port Versus Multiport Laparoscopic Surgery for Colon Cancer: The SIMPLE Multicenter Randomized Clinical Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable

2020 EvidenceUpdates

8. A systematic mixed studies review of health behaviour change interventions in colorectal cancer survivors

A systematic mixed studies review of health behaviour change interventions in colorectal cancer survivors A systematic mixed studies review of health behaviour change interventions in colorectal cancer survivors - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library of Medicine National (...) RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Review J Adv Nurs Actions . 2020 Apr 13. doi: 10.1111/jan.14389. Online ahead of print. A systematic mixed studies review of health behaviour change interventions in colorectal cancer survivors , , , Affiliations Expand Affiliation 1 School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada. PMID: 32281687 DOI: Item in Clipboard Review A systematic mixed studies review

2020 EvidenceUpdates

9. Ripretinib (Qinlock) - To treat advanced gastrointestinal-stromal tumors

Ripretinib (Qinlock) - To treat advanced gastrointestinal-stromal tumors Drug Approval Package: QINLOCK U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: QINLOCK Company: Deciphera Pharmaceuticals, LLC Application Number: 213973 Approval Date: 05/15/2020 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF) (PDF

2020 FDA - Drug Approval Package

10. Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. Full Text available with Trip Pro

Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. Lynch syndrome is associated with an increased risk of colorectal cancer and with a broader spectrum of cancers, especially endometrial cancer. In 2011, our group reported long-term cancer outcomes (mean follow-up 55·7 months [SD 31·4]) for participants with Lynch syndrome enrolled (...) outcomes were monitored for at least 10 years from recruitment with English, Finnish, and Welsh participants being monitored for up to 20 years. The primary endpoint was development of colorectal cancer. Analysis was by intention to treat and per protocol. The trial is registered with the ISRCTN registry, number ISRCTN59521990.Between January, 1999, and March, 2005, 937 eligible patients with Lynch syndrome, mean age 45 years, commenced treatment, of whom 861 agreed to be randomly assigned

2020 Lancet

11. Simultaneous Versus Delayed Resection for Initially Resectable Synchronous Colorectal Cancer Liver Metastases: A Prospective, Open-label, Randomized, Controlled Trial

of Digestive, Endocrine, Oncologic and Liver Transplant Surgery, University Hospital, François Rabelais University, Tours, France. 10 Department of Hepatobiliary, Oncologic and Transplant Surgery, AP-HP, Paul Brousse Hospital, Paris-Sud University, Villejuif, France. PMID: 32209911 DOI: Item in Clipboard Full-text links Cite Abstract Objective: To answer whether synchronous colorectal cancer liver metastases (SLM) should be resected simultaneously with primary cancer or should be delayed. Summary (...) background data: Numerous studies have compared both strategies. All were retrospective and conclusions were contradictory. Methods: Adults with colorectal cancer and resectable SLM were randomly assigned to either simultaneous or delayed resection of the metastases. The primary outcome was the rate of major complications within 60 days following surgery. Secondary outcomes included overall and disease-free survival. Results: A total of 105 patients were recruited. Eighty-five patients (39 and 46

2020 EvidenceUpdates

12. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, rand Full Text available with Trip Pro

: TRIBE2 was an open-label, phase 3, randomised study of patients aged 18-75 years with an Eastern Cooperative Oncology Group (ECOG) performance status of 2, with unresectable, previously untreated metastatic colorectal cancer, recruited from 58 Italian oncology units. Patients were stratified according to centre, ECOG performance status, primary tumour location, and previous adjuvant chemotherapy. A randomisation system incorporating a minimisation algorithm was used to randomly assign patients (1:1 (...) , and one sepsis). Interpretation: Upfront FOLFOXIRI plus bevacizumab followed by the reintroduction of the same regimen after disease progression seems to be a preferable therapeutic strategy to sequential administration of chemotherapy doublets, in combination with bevacizumab, for patients with metastatic colorectal cancer selected according to the study criteria. Funding: The GONO Cooperative Group, the ARCO Foundation, and F Hoffmann-La Roche. Copyright © 2020 Elsevier Ltd. All rights reserved

2020 EvidenceUpdates

13. Long-Term Colorectal Cancer Incidence and Mortality After a Single Negative Screening Colonoscopy. (Abstract)

Long-Term Colorectal Cancer Incidence and Mortality After a Single Negative Screening Colonoscopy. Current guidelines recommend a 10-year interval between screening colonoscopies, but evidence is limited.To assess the long-term risk for colorectal cancer (CRC) and death from CRC after a high- and low-quality single negative screening colonoscopy.Observational study.Polish Colonoscopy Screening Program.Average-risk individuals aged 50 to 66 years who had a single negative colonoscopy (...) (no neoplastic findings).Standardized incidence ratios (SIRs) and standardized mortality ratios (SMRs) of CRC after high- and low-quality single negative screening colonoscopy. High-quality colonoscopy included a complete examination, with adequate bowel preparation, performed by endoscopists with an adenoma detection rate of 20% or greater.Among 165 887 individuals followed for up to 17.4 years, CRC incidence (0.28 [95% CI, 0.25 to 0.30]) and mortality (0.19 [CI, 0.16 to 0.21]) were 72% and 81% lower

2020 Annals of Internal Medicine

14. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial

TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial TAS-102 With or Without Bevacizumab in Patients With Chemorefractory Metastatic Colorectal Cancer: An Investigator-Initiated, Open-Label, Randomised, Phase 2 Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other (...) for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation Lancet Oncol Actions . 2020 Mar;21(3):412-420. doi: 10.1016/S1470-2045(19)30827-7. Epub 2020 Jan 27. TAS-102 With or Without Bevacizumab in Patients With Chemorefractory Metastatic Colorectal Cancer: An Investigator-Initiated, Open-Label, Randomised, Phase 2 Trial , , , , , , , , , Affiliations Expand Affiliations 1 Department of Oncology, Odense University Hospital, Odense, Denmark; Department

2020 EvidenceUpdates

15. Effect of Multimodal Prehabilitation vs Postoperative Rehabilitation on 30-Day Postoperative Complications for Frail Patients Undergoing Resection of Colorectal Cancer: A Randomized Clinical Trial

Effect of Multimodal Prehabilitation vs Postoperative Rehabilitation on 30-Day Postoperative Complications for Frail Patients Undergoing Resection of Colorectal Cancer: A Randomized Clinical Trial Effect of Multimodal Prehabilitation vs Postoperative Rehabilitation on 30-Day Postoperative Complications for Frail Patients Undergoing Resection of Colorectal Cancer: A Randomized Clinical Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete (...) results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation JAMA Surg Actions . 2020 Jan 22;155(3):233-242. doi: 10.1001/jamasurg.2019.5474. Online ahead of print. Effect of Multimodal Prehabilitation vs Postoperative Rehabilitation on 30-Day Postoperative Complications for Frail Patients Undergoing Resection of Colorectal Cancer: A Randomized Clinical Trial

2020 EvidenceUpdates

16. Recommendations for Follow-Up After Colonoscopy and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer

adenomas 5 mm in size. Future studies may clarify whether length- ening the interval beyond 10 years may be possible. A 10- year follow-up after normal colonoscopy is recommended regardless of indication for the colonoscopy, except for in- dividuals at increased risk for CRC, such as those with his- tory of a hereditary CRC syndrome, personal history of in?ammatory bowel disease, personal history of hereditary cancer syndrome, serrated polyposis syndrome, malignant polyp, personal history of CRC (...) is in keeping with their values and preferences. This article does not include recommendations for follow-up for individuals with hereditary CRC syndromes (eg, Lynch syndrome and familial adenomatous polyposis), in?ammatory bowel disease, a personal history of CRC (includingmalignantpolyps),familyhistoryofCRCorcolo- rectal neoplasia, or serrated polyposis syndrome. As such, our recommendations for follow-up after colonoscopy and polypectomy do not apply to these groups except in cases where polyp ?ndings

2020 American Society for Gastrointestinal Endoscopy

17. Endoscopic Removal of Colorectal Lesions—Recommendations by the US Multi-Society Task Force on Colorectal Cancer

?brosis,local residual early carcinoma after endoscopic resection, and non-polypoid colorectal dysplasia in patients with in?ammatory bowel disease. 109 The technique of ESD involves an endoscopic knife for cuttingandsubmucosalinjectantforlifting.Aftersubmuco- sal injection, a circumferential incision is performed to isolate the lesion with 3 or 4 mm surrounding normal mu- cosa. The submucosa under the lesion is injected further. With controlled movements under direct view facilitated with the use (...) months to assess for local recurrence and to clear the colon of synchronous lesions. There is a very high prevalence of synchronous disease in patients with lesions 20 mm. In a large EMR referral cohort with lesions 20 mm, patients had an average of 4 additional conventional adenomas; 40% had an additional advanced adenoma; 20% had an additional lesion 20 mm; and 0.8% had a synchronous cancer not detected by the refer- ring physician. Of those referred for removal of a serrated lesion, 30% had

2020 American Society for Gastrointestinal Endoscopy

18. Regional Therapies for Colorectal Cancer Liver Metastases

Regional Therapies for Colorectal Cancer Liver Metastases Guideline 2-30a A Quality Initiative of the Program in Evidence-Based Care (PEBC), Ontario Health (Cancer Care Ontario) Regional Therapies for Colorectal Cancer Liver Metastases P. Karanicolas, R. Beecroft, R. Cosby, E. David, M. Kalyvas, E. Kennedy, G. Sapisochin, R. Wong, K. Zbuk and the Gastrointestinal Disease Site Group Report Date: March 10, 2020 For information about this document, please contact Dr. Paul Karanicolas or Dr. Robert (...) randomization to disease progression. Guideline 2-30a Section 3: Guideline Methods Overview - March 10, 2020 Page 9 Regional Therapies for Colorectal Cancer Liver Metastases Section 3: Guideline Methods Overview This section summarizes the methods used to create the guideline. For the systematic review, see Section 4. THE PROGRAM IN EVIDENCE-BASED CARE The PEBC is an initiative of the Ontario provincial cancer system, Ontario Health (Cancer Care Ontario) (OH [CCO]). The PEBC mandate is to improve the lives

2020 Cancer Care Ontario

19. Treatment of Patients with Late-Stage Colorectal Cancer Resource-Stratified Guideline Full Text available with Trip Pro

emergency colon or rectal cancer surgery. If resection is not possible, then patients should receive palliative care. , Palliative colostomy should be considered in situations of malignant bowel obstruction. In the assessment of general symptoms, clinicians should determine a patient’s performance status and comorbid conditions, as they can influence the ability to receive and predict the benefit from medical treatment. Diagnosis Recommendations on the methods of diagnosis for patients with colorectal (...) biomarker evaluation guideline. - TABLE 3 Recommendations on Symptom Management TABLE 4 Recommendations on Diagnosis TABLE 5 Recommendations on Staging Symptom Management Recommendations for assisting patients with symptoms of advanced colorectal cancer such as pain or bleeding are in . Discussion. More than 1.8 million patients in the world were diagnosed with colorectal cancer (CRC) in 2018. Among all patients with CRC, 20%-30% have metastatic disease from the outset (synchronous primary tumor

2020 American Society of Clinical Oncology Guidelines

20. Role of gastrointestinal endoscopy in the screening of digestive tract cancers in Europ

because of palliative treatment and new biological treatments for advanced disease. BetterunderstandingofthenaturalhistoryofGIcancershas shown that most of them are preceded by slowly progressing precancerous conditions or lesions, as well as by early invasive stages, therefore providing opportunities for effective inter- ventions. Beyond the classic adenoma–carcinoma sequence for colorectal carcinogenesis, similar pathways based on metaplasia–dysplasia–cancer progression have been shown for upper GI (...) leadtounderuseorpoorresourcingofhealthfacilities involved inprovidingscreeningservices, with consequent failuretofully realizethe potential benefits to patients. Methods In 2017, the European Society of Gastrointestinal Endoscopy (ESGE) Governing Board established a task force (Public Affairs Working Group led by A.S.) to produce a Position Statement concerning the value of endoscopy for screening purposes in GI cancers. The most prevalent digestive cancers (esophageal squamous cellcarcinoma,esophagealadenocarcinoma,gastric carcinoma

2020 European Society of Gastrointestinal Endoscopy